

1 **Genomic and phenotypic analysis of COVID-19-associated pulmonary aspergillosis isolates**  
2 **of *Aspergillus fumigatus***

3  
4 Jacob L. Steenwyk<sup>1</sup>, Matthew E. Mead<sup>1</sup>, Patrícia Alves de Castro<sup>2</sup>, Clara Valero<sup>2</sup>, André  
5 Damasio<sup>3,4</sup>, Renato A. C. dos Santos<sup>2</sup>, Abigail L. Labella<sup>1</sup>, Yuanning Li<sup>1</sup>, Sonja L. Knowles<sup>5</sup>,  
6 Huzefa A. Raja<sup>5</sup>, Nicholas H. Oberlies<sup>5</sup>, Xiaofan Zhou<sup>6</sup>, Oliver A. Cornely<sup>7,8,9,10</sup>, Frieder  
7 Fuchs<sup>11</sup>, Philipp Koehler<sup>7,8,\*</sup>, Gustavo H. Goldman<sup>2,\*</sup>, & Antonis Rokas<sup>1,\*</sup>

8  
9 <sup>1</sup>Department of Biological Sciences, Vanderbilt University, Nashville, Tennessee, USA

10 <sup>2</sup>Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão  
11 Preto, Brazil

12 <sup>3</sup>Institute of Biology, University of Campinas (UNICAMP), Campinas-SP, Brazil

13 <sup>4</sup>Experimental Medicine Research Cluster (EMRC), University of Campinas (UNICAMP),  
14 Campinas-SP, Brazil

15 <sup>5</sup>Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, North  
16 Carolina 27402

17 <sup>6</sup>Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Province Key Laboratory  
18 of Microbial Signals and Disease Control, Integrative Microbiology Research Centre, South  
19 China Agricultural University, Guangzhou, China

20 <sup>7</sup>University of Cologne, Medical Faculty and University Hospital Cologne, Department I of  
21 Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany

22 <sup>8</sup>University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-  
23 Associated Diseases (CECAD), Cologne, Germany

24 <sup>9</sup>ZKS Köln, Clinical Trials Centre Cologne, Cologne, Germany

25 <sup>10</sup>German Center for Infection Research (DZIF), Partner Site Bonn □ Cologne, Medical Faculty  
26 and University Hospital Cologne, University of Cologne, Cologne, Germany

27 <sup>11</sup>Faculty of Medicine, Institute for Medical Microbiology, Immunology and Hygiene, University  
28 of Cologne, Cologne, Germany

29  
30 \* Correspondence: [philipp.koehler@uk-koeln.de](mailto:philipp.koehler@uk-koeln.de), [ggoldman@usp.br](mailto:ggoldman@usp.br) and

31 [antonis.rokas@vanderbilt.edu](mailto:antonis.rokas@vanderbilt.edu)

32 **Abstract**

33 The ongoing global pandemic caused by the severe acute respiratory syndrome coronavirus 2  
34 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) first described from  
35 Wuhan, China. A subset of COVID-19 patients has been reported to have acquired secondary  
36 infections by microbial pathogens, such as fungal opportunistic pathogens from the genus  
37 *Aspergillus*. To gain insight into COVID-19 associated pulmonary aspergillosis (CAPA), we  
38 analyzed the genomes and characterized the phenotypic profiles of four CAPA isolates of  
39 *Aspergillus fumigatus* obtained from patients treated in the area of North Rhine-Westphalia,  
40 Germany. By examining the mutational spectrum of single nucleotide polymorphisms, insertion-  
41 deletion polymorphisms, and copy number variants among 206 genes known to modulate *A.*  
42 *fumigatus* virulence, we found that CAPA isolate genomes do not exhibit major differences from  
43 the genome of the Af293 reference strain. By examining virulence in an invertebrate moth  
44 model, growth in the presence of osmotic, cell wall, and oxidative stressors, and the minimum  
45 inhibitory concentration of antifungal drugs, we found that CAPA isolates were generally, but  
46 not always, similar to *A. fumigatus* reference strains Af293 and CEA17. Notably, CAPA isolate  
47 D had more putative loss of function mutations in genes known to increase virulence when  
48 deleted (e.g., in the *FLEA* gene, which encodes a lectin recognized by macrophages). Moreover,  
49 CAPA isolate D was significantly more virulent than the other three CAPA isolates and the *A.*  
50 *fumigatus* reference strains tested. These findings expand our understanding of the genomic and  
51 phenotypic characteristics of isolates that cause CAPA.

52

53 **Keywords**

54 pathogenicity, co-infection, secondary infection, virulence factors, superinfection, acute  
55 respiratory distress syndrome, *Aspergillus*,

## 56 **Introduction**

57 On March 11, 2020, the World Health Organization declared the ongoing pandemic caused by  
58 SARS-CoV-2, which causes COVID-19, a global emergency (Sohrabi et al., 2020). Similar to  
59 other viral infections, patients may be more susceptible to microbial secondary infections, which  
60 can complicate disease management strategies and result in adverse patient outcomes  
61 (Brüggemann et al., 2020; Cox et al., 2020). For example, approximately one quarter of patients  
62 infected with the H1N1 influenza virus during the 2009 pandemic were also infected with  
63 bacteria or fungi (MacIntyre et al., 2018; Zhou et al., 2020). Among studies examining patients  
64 with COVID-19, ~17% of individuals also have bacterial infections (Langford et al., 2020) and  
65 one study found that ~40% of patients with severe COVID-19 pneumonia were also infected  
66 with filamentous fungi from the genus *Aspergillus* (Nasir et al., 2020). Another study reported  
67 that ~26% of patients with acute respiratory distress syndrome-associated COVID-19 were also  
68 infected with *Aspergillus fumigatus* and had high rates of mortality (Koehler et al., 2020).  
69 Despite the prevalence microbial infections and their association with adverse patient outcomes,  
70 these secondary infections are only beginning to be understood.

71  
72 Invasive pulmonary aspergillosis is caused by tissue infiltration of Aspergilli after inhalation of  
73 asexual spores (Figure 1); more than 250,000 aspergillosis infections are estimated to occur  
74 annually and have high mortality rates (Bongomin et al., 2017). The major etiological agent of  
75 aspergillosis is *A. fumigatus* (Latgé and Chamilos, 2019), although a few other *Aspergillus*  
76 species are also known to cause aspergillosis (Bastos et al., 2020; dos Santos et al., 2020b; Rokas  
77 et al., 2020; Steenwyk et al., 2020c). Numerous factors are known to be associated with *A.*  
78 *fumigatus* pathogenicity, including its ability to grow at the human body temperature (37°C) and  
79 withstand oxidative stress (Kamei and Watanabe, 2005; Tekaiia and Latgé, 2005; Shwab et al.,  
80 2007; Losada et al., 2009; Abad et al., 2010; Grahl et al., 2012; Yin et al., 2013; Wiemann et al.,  
81 2014; Knox et al., 2016; Kowalski et al., 2019; Raffa and Keller, 2019; Blachowicz et al., 2020).  
82 Disease management of *A. fumigatus* is further complicated by resistance to antifungal drugs  
83 among strains (Chamilos and Kontoyiannis, 2005; Howard and Arendrup, 2011; Chowdhary et  
84 al., 2014; Sewell et al., 2019) Additionally, *A. fumigatus* strains have been previously shown to  
85 exhibit strain heterogeneity with respect to virulence and pathogenicity-associated traits  
86 (Kowalski et al., 2016; Keller, 2017; Kowalski et al., 2019; Ries et al., 2019; dos Santos et al.,

87 2020b; Steenwyk et al., 2020d). However, it remains unclear whether the genomic and  
88 pathogenicity-related phenotypic characteristics of CAPA isolates are similar or distinct from  
89 those of previously studied clinical strains of *A. fumigatus*.

90  
91 To address this question and gain insight into the pathobiology of *A. fumigatus* CAPA isolates,  
92 we examined the genomic and phenotypic characteristics of four CAPA isolates obtained from  
93 four critically ill patients of two different centers in Cologne, Germany (Koehler et al., 2020)  
94 (Table 1). All patients were submitted to intensive care units due to moderate to severe  
95 respiratory distress syndrome (ARDS). Genome-scale phylogenetic (or phylogenomic) analyses  
96 revealed CAPA isolates formed a monophyletic group closely related to reference strains Af293  
97 and A1163. Examination of the mutational spectra of 206 genes known to modulate virulence in  
98 *A. fumigatus* (which are hereafter referred to as genetic determinants of virulence) revealed  
99 several putative loss of function (LOF) mutations. Notably, CAPA isolate D had the most  
100 putative LOF mutations among genes whose null mutants are known to increase virulence. The  
101 profiles of pathogenicity-related traits of the CAPA isolates were similar to those of reference *A.*  
102 *fumigatus* strains Af293 and CEA17. One notable exception was that CAPA isolate D was  
103 significantly more virulent than other strains in an invertebrate model of disease. These results  
104 suggest that the genomes of *A. fumigatus* CAPA isolates contain nearly complete and intact  
105 repertoires of genetic determinants of virulence and have phenotypic profiles that are broadly  
106 expected for *A. fumigatus* clinical isolates. However, we did find evidence for genetic and  
107 phenotypic strain heterogeneity. These results suggest the CAPA isolates show similar virulence  
108 profiles as *A. fumigatus* clinical strains Af293 and A1163 and expand our understanding of  
109 CAPA.

110

## 111 **Results and Discussion**

### 112 **CAPA isolates belong to *A. fumigatus* and are closely related to reference strains Af293 and** 113 **A1163**

114 To confirm that the CAPA isolates belong to *A. fumigatus*, we sequenced, assembled, and  
115 annotated their genomes (Table S1). Phylogenetic analyses conducted using *tef1* (Figure S1) and  
116 calmodulin (Figure S2) sequences suggested that all CAPA isolates are *A. fumigatus*.

117 Phylogenomic analysis using 50 *Aspergillus* genomes (the four CAPA isolates, 43 representative

118 *A. fumigatus* genomes including strains Af293 and A1163 (Nierman et al., 2005; Fedorova et al.,  
119 2008; Liu et al., 2011; Abdolrasouli et al., 2015; Knox et al., 2016; Lind et al., 2017; Paul et al.,  
120 2017; dos Santos et al., 2020b), *A. fischeri* strains NRRL 181 and NRRL 4585, and *A.*  
121 *oerlinghausenensis* strain CBS 139183<sup>T</sup> (Fedorova et al., 2008; Steenwyk et al., 2020d))  
122 confirmed that all CAPA isolates are *A. fumigatus* (Figure 2A). Phylogenomic analyses also  
123 revealed the CAPA isolates formed a monophyletic group closely related to reference strains  
124 Af293 and A1163.

125

### 126 **CAPA isolate genomes contain polymorphisms in genetic determinants of virulence and** 127 **biosynthetic gene clusters**

128 Sequence similarity searches of gene sequences present in a curated list of 206 genetic  
129 determinants of virulence previously identified in *A. fumigatus* (File S1) (Abad et al., 2010;  
130 Bignell et al., 2016; Kjærboelling et al., 2018; Mead et al., 2019; Urban et al., 2019) showed that  
131 all 206 genes were present in the genomes of the CAPA isolates. Furthermore, none of the 206  
132 genetic determinants of virulence showed any copy number variation among CAPA isolates.  
133 Examination of single nucleotide polymorphisms (SNPs) and insertion/deletion (indel)  
134 polymorphisms coupled with variant effect prediction in these 206 genes (Figure 2B; File S2)  
135 showed that all CAPA isolates shared multiple polymorphisms resulting in early stop codons or  
136 frameshift mutations suggestive of loss of function (LOF) in *NRPS8* (AFUA\_5G12730), a  
137 nonribosomal peptide synthetase gene that encodes an unknown secondary metabolite (Lind et  
138 al., 2017). LOF mutations in *NRPS8* are known to result in increased virulence in a mouse model  
139 of disease (O’Hanlon et al., 2011). Putative LOF mutations were also observed in genes whose  
140 null mutants decreased virulence. For example, all CAPA isolates shared the same SNPs  
141 resulting in early stop codons that likely result in LOF in *PPTA* (AFUA\_2G08590), a putative  
142 4’-phosphopantetheinyl transferase, whose deletion results in reduced virulence in a mouse  
143 model of disease (Johns et al., 2017). In light of the close evolutionary relationships among  
144 CAPA isolates, we hypothesize that these shared mutations likely occurred in the genome of  
145 their most recent common ancestor.

146

147 In addition to shared polymorphisms, analyses of CAPA isolate genomes also revealed isolate-  
148 specific polymorphisms affecting genetic determinants of virulence (File S2). For example,

149 SNPs resulting in early stop codons, which likely lead to LOF, were observed in *CYP5081A1*  
150 (AFUA\_4G14780), a putative cytochrome P450 monooxygenase, in CAPA isolates B and C.  
151 *CYP5081A1* LOF is associated with reduced virulence of *A. fumigatus* (Mitsuguchi et al., 2009).  
152 Additionally, a mutation resulting in the loss of the start codon was observed in *FLEA*  
153 (AFUA\_5G14740), a gene that encodes an L-fucose-specific lectin, in only CAPA isolate D.  
154 Notably, mice infected with *FLEA* null mutants have more severe pneumonia and invasive  
155 aspergillosis than wild-type strains. *FLEA* null mutants cause more severe disease because FleA  
156 binds to macrophages and therefore is critical for host recognition, clearance, and macrophage  
157 killing (Kerr et al., 2016). Most notably, CAPA isolate D had the most putative LOF mutations  
158 in the subset of the 206 genetic determinants whose null mutants result in increased virulence,  
159 which raises the hypothesis that CAPA isolate D is more virulent than the other CAPA isolates.

160

161 Examination of the presence of biosynthetic gene clusters (BGCs) revealed that all CAPA  
162 isolates had BGCs that encode secondary metabolites known to modulate host biology (Table 2).  
163 For example, all CAPA isolates had BGCs encoding the toxic secondary metabolite gliotoxin  
164 (Figure 3). Other intact BGCs in the genomes of the CAPA isolates include fumitremorgin,  
165 trypacidin, pseurotin, and fumagillin, which are known to modulate host biology (Ishikawa et al.,  
166 2009; González-Lobato et al., 2010; Gauthier et al., 2012); for example, fumagillin is known to  
167 inhibit neutrophil function (Fallon et al., 2010, 2011). More broadly, all CAPA isolates had  
168 similar numbers and classes of BGCs (Figure S3).

169

170 In summary, we found that CAPA isolates were closely related to one another and had largely  
171 intact genetic determinants of virulence and BGCs. However, we observed strain specific  
172 polymorphisms in known genetic determinants of virulence in CAPA isolate genomes, which  
173 raises the hypothesis that CAPA isolates differ in their virulence profiles.

174

### 175 **CAPA isolates display strain heterogeneity in virulence but not in virulence-related traits**

176 Examination of virulence and virulence-related traits revealed the CAPA isolates often, but not  
177 always, had similar phenotypic profiles compared to reference *A. fumigatus* strains Af293 and  
178 CEA17 (which is a *pyrG* mutant derived from the reference strain A1163 (Bertuzzi et al., 2020)).  
179 For example, virulence in the *Galleria* moth model of fungal disease revealed strain



180 heterogeneity among CAPA isolates, Af293, and CEA17 ( $p < 0.001$ ; log-rank test; Figure 4A).  
181 Pairwise examination revealed that the observed strain heterogeneity was primarily driven by  
182 CAPA isolate D, which was significantly more virulent than all other CAPA isolates (Benjamini-  
183 Hochberg adjusted  $p$ -value  $< 0.01$  when comparing CAPA isolate D to another isolate; log-rank  
184 test; File S3). Also, CAPA isolate C was significantly more virulent than reference strain Af293  
185 (Benjamini-Hochberg adjusted  $p$ -value = 0.01; log-rank test). These results reveal that the CAPA  
186 isolates have generally similar virulence profiles compared to the reference strains Af293 and  
187 CEA17 with the exception of the more virulent CAPA isolate D.

188  
189 Examination of growth in the presence of osmotic, cell wall, and oxidative stressors revealed that  
190 CAPA isolates had similar phenotypic profiles compared to Af293 and CEA17 (Figures 4B-D  
191 and S4) with one exception. Specifically, across all growth assays, we observed significant  
192 differences between the CAPA isolates and the reference strains Af293 and CEA17 ( $p < 0.001$ ;  
193 multi-factor ANOVA). Pairwise comparisons revealed significant differences were driven by  
194 growth in the presence of calcofluor white wherein the CAPA isolates were more sensitive than  
195 reference strains Af293 and CEA17 ( $p < 0.001$ ; Tukey's Honest Significant Difference test;  
196 Figure 4C). Lastly, antifungal drug susceptibility profiles for amphotericin B, voriconazole,  
197 itraconazole, and posaconazole were similar between the CAPA isolates and reference strains  
198 Af293 and CEA17 (Table 3).

199  
200 In summary, we found that the CAPA isolates have similar phenotypic profiles compared to  
201 reference strains Af293 and CEA17 with the exception of growth in the presence of calcofluor  
202 white and the greater virulence of CAPA isolate D. The higher levels of virulence observed in  
203 CAPA isolate D may be associated with a greater number of putative LOF mutations that are  
204 known to increase virulence; however, this hypothesis requires further functional testing.

## 205 206 **Concluding remarks**

207 The effects of secondary fungal infections in COVID-19 patients are only beginning to be  
208 understood. Our results revealed that CAPA isolates are generally, but not always, similar to *A.*  
209 *fumigatus* clinical reference strains. Notably, CAPA isolate D was significantly more virulent  
210 than the other three CAPA isolates and two reference strains examined. We hypothesize that this

211 difference is because the D isolate contains more putative LOF mutations in genetic determinants  
212 of virulence whose null mutants are known to increase virulence than other strains. Taken  
213 together, these results are important to consider in the management of fungal infections among  
214 patients with COVID-19, especially those infected with *A. fumigatus*, and broaden our  
215 understanding of CAPA.

216

## 217 **Methods**

### 218 **Patient information and ethics approval**

219 Patients were included into the FungiScope® global registry for emerging invasive fungal  
220 infections ([www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), NCT 01731353). The clinical trial is approved by the Ethics  
221 Committee of the University of Cologne, Cologne, Germany (Study ID: 05-102) (Seidel et al.,  
222 2017). Since 2019, patients with invasive aspergillosis are also included.

223

### 224 **DNA quality control, library preparation, and sequencing**

225 Sample DNA concentration was measured by Qubit fluorometer and DNA integrity and purity  
226 by agarose gel electrophoresis. For each sample, 1-1.5µg genomic DNA was randomly  
227 fragmented by Covaris and fragments with average size of 200-400bp were selected by  
228 Agencourt AMPure XP-Medium kit. The selected fragments were end-repaired, 3' adenylated,  
229 adapters-ligated, and amplified by PCR. Double-stranded PCR products were recovered by the  
230 AxyPrep Mag PCR clean up Kit, and then heat denatured and circularized by using the splint  
231 oligo sequence. The single-strand circle DNA (ssCir DNA) products were formatted as the final  
232 library and went through further QC procedures. The libraries were sequenced on the  
233 MGISEQ2000 platform.

234

### 235 **Genome assembly and annotations**

236 Short-read sequencing data of each sample were assembled using MaSuRCA, v3.4.1 (Zimin et  
237 al., 2013). Each *de novo* genome assembly was annotated using the MAKER genome annotation  
238 pipeline, v2.31.11 (Holt and Yandell, 2011), which integrates three *ab initio* gene predictors:  
239 AUGUSTUS, v3.3.3 (Stanke and Waack, 2003), GeneMark-ES, v4.59 (Besemer and  
240 Borodovsky, 2005), and SNAP, v2013-11-29 (Korf, 2004). Fungal protein sequences in the  
241 SwissProt database (release 2020\_02) were used as homology evidence for the genome



242 annotation. The MAKER annotation process occurs in an iterative manner as described  
243 previously (Shen et al., 2018). In brief, for each genome, repeats were first soft-masked using  
244 RepeatMasker v4.1.0 (<http://www.repeatmasker.org>) with the library Repbase library release-  
245 20181026 and the “-species” parameter set to “*Aspergillus fumigatus*”. GeneMark-ES was then  
246 trained on the masked genome sequence using the self-training option (“--ES”) and the branch  
247 model algorithm (“--fungus”), which is optimal for fungal genome annotation. On the other  
248 hand, an initial MAKER analysis was carried out where gene annotations were generated directly  
249 from homology evidence, and the resulting gene models were used to train both AUGUSTUS  
250 and SNAP. Once trained, the ab initio predictors were used together with homology evidence to  
251 conduct a first round of full MAKER analysis. Resulting gene models supported by homology  
252 evidence were used to re-train AUGUSTUS and SNAP. A second round of MAKER analysis  
253 was conducted using the newly trained AUGUSTUS and SNAP parameters, and once again the  
254 resulting gene models with homology supports were used to re-train AUGUSTUS and SNAP.  
255 Finally, a third round of MAKER analysis was performed using the new AUGUSTUS and  
256 SNAP parameters to generate the final set of annotations for the genome. The completeness of *de*  
257 *novo* genome assemblies and *ab initio* gene predictions was assessed using BUSCO, v4.1.2  
258 (Waterhouse et al., 2018) using 4,191 pre-selected ‘nearly’ universally single-copy orthologous  
259 genes from the Eurotiales database (eurotiales\_odb10.2019-11-20) in OrthoDB, v10.1  
260 (Waterhouse et al., 2013).

261

### 262 **Polymorphism identification**

263 To characterize and examine the putative impact of polymorphisms in the genomes of the CAPA  
264 isolates, we identified single nucleotide polymorphisms (SNPs), insertion-deletion  
265 polymorphisms (indels), and copy number (CN) polymorphisms. To do so, reads were first  
266 quality-trimmed and mapped to the genome of *A. fumigatus* Af293 (RefSeq assembly accession:  
267 GCF\_000002655.1) following a previously established protocol (Steenwyk and Rokas, 2017).  
268 Specifically, reads were first quality-trimmed with Trimmomatic, v0.36 (Bolger et al., 2014),  
269 using the parameters leading:10, trailing:10, slidingwindow:4:20, minlen:50. The resulting  
270 quality-trimmed reads were mapped to the *A. fumigatus* Af293 genome using the Burrows-  
271 Wheeler Aligner (BWA), v0.7.17 (Li, 2013), with the mem parameter. Thereafter, mapped reads

272 were converted to a sorted bam and mpileup format for polymorphism identification using  
273 SAMtools, v.1.3.1 (Li et al., 2009).

274  
275 To identify SNPs and indels, mpileup files were used as input into VarScan, v2.3.9 (Koboldt et  
276 al., 2012), with the mpileup2snp and mpileup2indel functions, respectively. To ensure only  
277 confident SNPs and indels were identified, a Fischer's Exact test p-value threshold of 0.05 and  
278 minimum variant allele frequency of 0.75 were used. The resulting Variant Call Format files  
279 were used as input to snpEff, v.4.3t (Cingolani et al., 2012), which predicted their functional  
280 impacts on gene function as high, moderate, or low. To identify CN variants, the sorted bam files  
281 were used as input into Control-FREEC, v9.1 (Boeva et al., 2011, 2012). The  
282 coefficientOfVariation parameter was set to 0.062 and window size was automatically  
283 determined by Control-FREEC. To ensure high-confidence in CN variant identification, a p-  
284 value threshold of 0.05 was used for both Wilcoxon Rank Sum and Kolmogorov Smirnov tests.

285

### 286 **Maximum likelihood molecular phylogenetics**

287 To taxonomically identify the species of *Aspergillus* sequenced, we conducted molecular  
288 phylogenetic analysis of two different loci and two different datasets. In the first analysis, the  
289 nucleotide sequence of the alpha subunit of translation elongation factor EF-1, *tef1* (NCBI  
290 Accession: XM\_745295.2), from the genome of *Aspergillus fumigatus* Af293 was used to extract  
291 other fungal *tef1* sequences from NCBI's fungal nucleotide reference sequence database  
292 (downloaded July 2020) using the blastn function from NCBI's BLAST+, v2.3.0 (Camacho et  
293 al., 2009). *Tef1* sequences were extracted from the CAPA isolates by identifying their best  
294 BLAST hit. Sequences from the top 100 best BLAST hits in the fungal nucleotide reference  
295 sequence database and the four *tef1* sequences from the CAPA isolates were aligned using  
296 MAFFT, v7.402 (Katoh and Standley, 2013) using previously described parameters (Steenwyk et  
297 al., 2019) with slight modifications. Specifically, the following parameters were used: --op 1.0 --  
298 maxiterate 1000 --retree 1 --genafpair. The resulting alignment was trimmed using ClipKIT, v0.1  
299 (Steenwyk et al., 2020b), with default 'gappy' mode. The trimmed alignment was then used to  
300 infer the evolutionary history of *tef1* sequences using IQ-TREE2 (Minh et al., 2020). The best  
301 fitting substitution model—TIM3 with empirical base frequencies, allowing for a proportion of  
302 invariable sites, and a discrete Gamma model (Yang, 1994; Gu et al., 1995) with four rate

303 categories (TIM3+F+I+G4)—was determined using Bayesian Information Criterion. In the  
304 second analysis, the same process was used to conduct molecular phylogenetic analysis using  
305 calmodulin nucleotide sequences from *Aspergillus* section *Fumigati* species and *Aspergillus*  
306 *clavatus*, an outgroup taxon, using sequences from NCBI that were made available elsewhere  
307 (dos Santos et al., 2020a). For calmodulin sequences, the best fitting substitution model was TNe  
308 (Tamura and Nei, 1993) with a discrete Gamma model with four rate categories (TNe+G4).  
309 Bipartition support was assessed using 5,000 ultrafast bootstrap support approximations (Hoang  
310 et al., 2018).

311  
312 To determine what strains of *A. fumigatus* the CAPA isolates were most similar to, we conducted  
313 phylogenomic analyses using the 50 *Aspergillus* proteomes. To do so, we first identified  
314 orthologous groups of genes across all 50 *Aspergillus* using OrthoFinder, 2.3.8 (Emms and  
315 Kelly, 2019). OrthoFinder takes as input the proteome sequence files from multiple genomes and  
316 conducts all-vs-all sequence similarity searches using DIAMOND, v0.9.24.125 (Buchfink et al.,  
317 2015). Our input included 50 total proteomes: 47 were *A. fumigatus*, two were *A. fischeri*, and  
318 one was *A. oerlinghausenensis* (Fedorova et al., 2008; Lind et al., 2017; Steenwyk et al., 2020d).  
319 OrthoFinder then clusters sequences into orthologous groups of genes using the graph-based  
320 Markov Clustering Algorithm (van Dongen, 2000). To maximize the number of single-copy  
321 orthologous groups of genes found across all input genomes, clustering granularity was explored  
322 by running 41 iterations of OrthoFinder that differed in their inflation parameter. Specifically,  
323 iterations of OrthoFinder inflation parameters were set to 1.0-5.0 with a step of 0.1. The lowest  
324 number of single-copy orthologous groups of genes was 3,399 when using an inflation parameter  
325 of 1.0; the highest number was 4,525 when using inflation parameter values of 3.8 and 4.1. We  
326 used the groups inferred using an inflation parameter of 3.8.

327  
328 Next, we built the phylogenomic data matrix and reconstructed evolutionary relationships among  
329 the 50 *Aspergillus* genomes. To do so, the protein sequences from 4,525 single-copy orthologous  
330 groups of genes were aligned using MAFFT, v7.402 (Kato and Standley, 2013), with the  
331 following parameters: --bl 62 --op 1.0 --maxiterate 1000 --retree 1 --genafpair. Next, nucleotide  
332 sequences were threaded onto the protein alignments using function `thread_dna` in PhyKIT,  
333 v0.0.1 (Steenwyk et al., 2020a). The resulting codon-based alignments were then trimmed using

334 ClipKIT, v0.1 (Steenwyk et al., 2020b), using the gappy mode. The resulting aligned and  
335 trimmed alignments were then concatenated into a single matrix with 7,133,367 sites using the  
336 PhyKIT function create\_concat. To reconstruct the evolutionary history of the 50 *Aspergillus*  
337 genomes, a single best-fitting model of sequence substitution and rate heterogeneity was  
338 estimated across the entire matrix using IQ-TREE2, v.2.0.6 (Minh et al., 2020). The best-fitting  
339 model was determined to be a general time reversible model with empirical base frequencies and  
340 invariable sites with a discrete Gamma model with four rate categories (GTR+F+I+G4) (Tavaré,  
341 1986; Gu et al., 1995; Waddell and Steel, 1997; Vinet and Zhedanov, 2011) using Bayesian  
342 Information Criterion. During tree search, the number of candidate trees maintained during  
343 maximum likelihood tree search was increased from five to ten. Five independent searches were  
344 conducted and the tree with the best log-likelihood score was chosen as the ‘best’ phylogeny.  
345 Bipartition support was evaluated using 5,000 ultrafast bootstrap approximations (Hoang et al.,  
346 2018).

347

#### 348 **Biosynthetic gene cluster prediction**

349 To predict BGCs in the genomes of *A. fumigatus* strains Af293 and the CAPA isolates, gene  
350 boundaries inferred by MAKER were used as input into antiSMASH, v4.1.0 (Weber et al.,  
351 2015). Using a previously published list of genes known to encode BGCs in the genome of *A.*  
352 *fumigatus* Af293 (Lind et al., 2017), BLAST-based searches using an expectation value  
353 threshold of 1e-10 were used to identify BGCs implicated in modulating host biology using  
354 NCBI’s BLAST+, v2.3.0 (Camacho et al., 2009). Among predicted BGCs that did not match the  
355 previously published list, we further examined their evolutionary history if at least 50% of genes  
356 showed similarity to species outside of the genus *Aspergillus*, which is information provided in  
357 the antiSMASH output. Using these criteria, no evidence suggestive of horizontally acquired  
358 BGCs from distant relatives was detected.

359

#### 360 **Infection of *Galleria mellonella***

361 Survival curves (n=12/strain) of *Galleria mellonella* infected with CAPA isolates A, B, C, and  
362 D. Phosphate buffered saline (PBS) without asexual spores (conidia) was administered as a  
363 negative control. A log-rank test was used to examine strain heterogeneity followed by pairwise  
364 comparisons with Benjamini-Hochberg multi-test correction (Benjamini and Hochberg, 1995).

365 All the selected larvae of *Galleria mellonella* were in the final (sixth) instar larval stage of  
366 development, weighing 275–330 milligram. Fresh conidia from each strain were harvested from  
367 minimal media (MM) plates in PBS solution and filtered through a Miracloth (Calbiochem). For  
368 each strain, the spores were counted using a hemocytometer and the stock suspension was done  
369 at  $2 \times 10^8$  conidia/milliliter. The viability of the administered inoculum was determined by  
370 plating a serial dilution of the conidia on MM medium at 37°C. A total of 5 microliters ( $1 \times 10^6$   
371 conidia/larva) from each stock suspension was inoculated per larva. The control group was  
372 composed of larvae inoculated with 5 microliters of PBS to observe the killing due to physical  
373 trauma. The inoculum was performed by using Hamilton syringe (7000.5KH) via the last left  
374 proleg. After infection, the larvae were maintained in petri dishes at 37°C in the dark and were  
375 scored daily. Larvae were considered dead by presenting the absence of movement in response to  
376 touch.

377

### 378 **Growth assays**

379 To examine growth conditions of the CAPA isolates and reference strains Af293 and A1163,  
380 plates were inoculated with  $10^4$  spores per strain and allowed to grow for five days on solid MM  
381 or MM supplemented with various concentrations of osmotic (sorbitol, NaCl), cell wall (congo  
382 red, calcofluor white and caspofungin), and oxidative stress agents (menadione and t-butyl) at  
383 37°C. MM had 1% (weight / volume) glucose, original high nitrate salts, trace elements, and a  
384 pH of 6.5; trace elements, vitamins, and nitrate salts compositions follow standards described  
385 elsewhere (Käfer, 1977). To correct for strain heterogeneity in growth rates, radial growth in  
386 centimeters in the presence of stressors was divided by radial growth in centimeters in the  
387 absence of the stressor.

388

### 389 **Data Availability**

390 Newly sequenced genomes assemblies, annotations, and raw short reads have been deposited to  
391 NCBI's GenBank database under BioProject accession PRJNA673120. Additional copies of  
392 genome assemblies, annotations, and gene coordinates have been uploaded to figshare (doi:  
393 10.6084/m9.figshare.13118549). Other raw data including the genome assembly and annotations  
394 of all analyzed *Aspergillus* genomes, the aligned and trimmed phylogenetic and phylogenomic  
395 data matrices, predicted BGCs, and other analysis have been uploaded to figshare as well.

396

397 **Conflict of Interest**

398 Oliver A. Cornely is supported by the German Federal Ministry of Research and Education, is  
399 funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under  
400 Germany's Excellence Strategy – CECAD, EXC 2030 – 390661388 and has received research  
401 grants from, is an advisor to, or received lecture honoraria from Actelion, Allegra Therapeutics,  
402 Al-Jazeera Pharmaceuticals, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis,  
403 F2G, Gilead, Grupo Biotoscana, IQVIA, Janssen, Matinas, Medicines Company, MedPace,  
404 Melinta Therapeutics, Menarini, Merck/MSD, Mylan, Nabriva, Noxxon, Octapharma, Paratek,  
405 Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi. Philipp Koehler has received non-  
406 financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the  
407 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases,  
408 University of Cologne, Cologne, Germany, and received lecture honoraria from or is advisor to  
409 Akademie für Infektionsmedizin e.V., Astellas Pharma, European Confederation of Medical  
410 Mycology, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH,  
411 Noxxon N.V., and University Hospital, LMU Munich outside the submitted work. Antonis  
412 Rokas is a Scientific Consultant for LifeMine Therapeutics, Inc.

413

414 **Acknowledgements**

415 We thank the Rokas and Goldman laboratories for support of this work and their helpful insight.  
416 J.L.S. and A.R. are supported by the Howard Hughes Medical Institute through the James H.  
417 Gilliam Fellowships for Advanced Study Program. A.R. received additional support from a  
418 Discovery grant from Vanderbilt University, the Burroughs Wellcome Fund, the National  
419 Science Foundation (DEB-1442113), and National Institutes of Health/National Institute of  
420 Allergy and Infectious Diseases (1R56AI146096-01A1). G.H.G. and A.D. thank Fundação de  
421 Amparo à Pesquisa do Estado de São Paulo (FAPESP) grant numbers 2016/07870-9 and  
422 2020/06151-4, and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq),  
423 both from Brazil. X.Z. is supported by the Key-Area Research and Development Program of  
424 Guangdong Province (2018B020206001). F.F. has a Clinician Scientist Position supported by the  
425 Deans Office, Faculty of Medicine, University of Cologne. C.V. is supported by FAPESP grant  
426 number 2018/00715-3. S.L.K. was supported by the National Center for Complementary and



427 Integrative Health, a component of the National Institutes of Health, under award number F31  
428 AT010558.

429 **References**

- 430 Abad, A., Victoria Fernández-Molina, J., Bikandi, J., Ramírez, A., Margareto, J., Sendino, J., et  
431 al. (2010). What makes *Aspergillus fumigatus* a successful pathogen? Genes and molecules  
432 involved in invasive aspergillosis. *Rev. Iberoam. Micol.* 27, 155–182.  
433 doi:10.1016/j.riam.2010.10.003.
- 434 Abdolrasouli, A., Rhodes, J., Beale, M. A., Hagen, F., Rogers, T. R., Chowdhary, A., et al.  
435 (2015). Genomic Context of Azole Resistance Mutations in *Aspergillus fumigatus*  
436 Determined Using Whole-Genome Sequencing. *MBio* 6, e00536. doi:10.1128/mBio.00536-  
437 15.
- 438 Bastos, R. W., Valero, C., Silva, L. P., Schoen, T., Drott, M., Brauer, V., et al. (2020).  
439 Functional Characterization of Clinical Isolates of the Opportunistic Fungal Pathogen  
440 *Aspergillus nidulans*. *mSphere* 5. doi:10.1128/mSphere.00153-20.
- 441 Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and  
442 Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B.* doi:10.1111/j.2517-  
443 6161.1995.tb02031.x.
- 444 Bertuzzi, M., van Rhijn, N., Krappmann, S., Bowyer, P., Bromley, M. J., and Bignell, E. M.  
445 (2020). On the lineage of *Aspergillus fumigatus* isolates in common laboratory use. *Med.*  
446 *Mycol.* doi:10.1093/mmy/myaa075.
- 447 Besemer, J., and Borodovsky, M. (2005). GeneMark: web software for gene finding in  
448 prokaryotes, eukaryotes and viruses. *Nucleic Acids Res.* 33, W451–W454.  
449 doi:10.1093/nar/gki487.
- 450 Bignell, E., Cairns, T. C., Throckmorton, K., Nierman, W. C., and Keller, N. P. (2016).  
451 Secondary metabolite arsenal of an opportunistic pathogenic fungus. *Philos. Trans. R. Soc.*  
452 *B Biol. Sci.* 371, 20160023. doi:10.1098/rstb.2016.0023.
- 453 Blachowicz, A., Raffa, N., Bok, J. W., Choera, T., Knox, B., Lim, F. Y., et al. (2020).  
454 Contributions of Spore Secondary Metabolites to UV-C Protection and Virulence Vary in  
455 Different *Aspergillus fumigatus* Strains. *MBio* 11. doi:10.1128/mBio.03415-19.
- 456 Boeva, V., Popova, T., Bleakley, K., Chiche, P., Cappo, J., Schleiermacher, G., et al. (2012).  
457 Control-FREEC: a tool for assessing copy number and allelic content using next-generation  
458 sequencing data. *Bioinformatics* 28, 423–425. doi:10.1093/bioinformatics/btr670.
- 459 Boeva, V., Zinovyev, A., Bleakley, K., Vert, J. P., Janoueix-Lerosey, I., Delattre, O., et al.

- 460 (2011). Control-free calling of copy number alterations in deep-sequencing data using GC-  
461 content normalization. *Bioinformatics* 27, 268–269. doi:10.1093/bioinformatics/btq635.
- 462 Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina  
463 sequence data. *Bioinformatics* 30, 2114–2120. doi:10.1093/bioinformatics/btu170.
- 464 Bongomin, F., Gago, S., Oladele, R., and Denning, D. (2017). Global and Multi-National  
465 Prevalence of Fungal Diseases—Estimate Precision. *J. Fungi* 3, 57.  
466 doi:10.3390/jof3040057.
- 467 Brüggemann, R. J., van de Veerdonk, F. L., and Verweij, P. E. (2020). The challenge of  
468 managing COVID-19 associated pulmonary aspergillosis. *Clin. Infect. Dis.*  
469 doi:10.1093/cid/ciaa1211.
- 470 Buchfink, B., Xie, C., and Huson, D. H. (2015). Fast and sensitive protein alignment using  
471 DIAMOND. *Nat. Methods* 12, 59–60. doi:10.1038/nmeth.3176.
- 472 Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., et al. (2009).  
473 BLAST+: architecture and applications. *BMC Bioinformatics* 10, 421. doi:10.1186/1471-  
474 2105-10-421.
- 475 Chamilos, G., and Kontoyiannis, D. P. (2005). Update on antifungal drug resistance mechanisms  
476 of *Aspergillus fumigatus*. *Drug Resist. Updat.* 8, 344–358. doi:10.1016/j.drup.2006.01.001.
- 477 Chowdhary, A., Sharma, C., Hagen, F., and Meis, J. F. (2014). Exploring azole antifungal drug  
478 resistance in *Aspergillus fumigatus* with special reference to resistance mechanisms. *Future*  
479 *Microbiol.* 9, 697–711. doi:10.2217/fmb.14.27.
- 480 Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., et al. (2012). A program  
481 for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. *Fly*  
482 (*Austin*). 6, 80–92. doi:10.4161/fly.19695.
- 483 Cox, M. J., Loman, N., Bogaert, D., and O’Grady, J. (2020). Co-infections: potentially lethal and  
484 unexplored in COVID-19. *The Lancet Microbe* 1, e11. doi:10.1016/S2666-5247(20)30009-  
485 4.
- 486 dos Santos, R. A. C., Rivero-Menendez, O., Steenwyk, J. L., Mead, M. E., Goldman, G. H.,  
487 Alastruey-Izquierdo, A., et al. (2020a). Draft Genome Sequences of Four *Aspergillus*  
488 Section *Fumigati* Clinical Strains. *Microbiol. Resour. Announc.* 9.  
489 doi:10.1128/MRA.00856-20.
- 490 dos Santos, R. A. C., Steenwyk, J. L., Rivero-Menendez, O., Mead, M. E., Silva, L. P., Bastos,

- 491 R. W., et al. (2020b). Genomic and Phenotypic Heterogeneity of Clinical Isolates of the  
492 Human Pathogens *Aspergillus fumigatus*, *Aspergillus lentulus*, and *Aspergillus*  
493 *fumigatiaffinis*. *Front. Genet.* 11. doi:10.3389/fgene.2020.00459.
- 494 Emms, D. M., and Kelly, S. (2019). OrthoFinder: phylogenetic orthology inference for  
495 comparative genomics. *Genome Biol.* 20, 238. doi:10.1186/s13059-019-1832-y.
- 496 Fallon, J. P., Reeves, E. P., and Kavanagh, K. (2010). Inhibition of neutrophil function following  
497 exposure to the *Aspergillus fumigatus* toxin fumagillin. *J. Med. Microbiol.* 59, 625–633.  
498 doi:10.1099/jmm.0.018192-0.
- 499 Fallon, J. P., Reeves, E. P., and Kavanagh, K. (2011). The *Aspergillus fumigatus* toxin  
500 fumagillin suppresses the immune response of *Galleria mellonella* larvae by inhibiting the  
501 action of haemocytes. *Microbiology* 157, 1481–1488. doi:10.1099/mic.0.043786-0.
- 502 Fedorova, N. D., Khaldi, N., Joardar, V. S., Maiti, R., Amedeo, P., Anderson, M. J., et al. (2008).  
503 Genomic islands in the pathogenic filamentous fungus *Aspergillus fumigatus*. *PLoS Genet.*  
504 4. doi:10.1371/journal.pgen.1000046.
- 505 Gauthier, T., Wang, X., Sifuentes Dos Santos, J., Fysikopoulos, A., Tadrict, S., Canlet, C., et al.  
506 (2012). Trypacidin, a Spore-Borne Toxin from *Aspergillus fumigatus*, Is Cytotoxic to Lung  
507 Cells. *PLoS One* 7, e29906. doi:10.1371/journal.pone.0029906.
- 508 González-Lobato, L., Real, R., Prieto, J. G., Álvarez, A. I., and Merino, G. (2010). Differential  
509 inhibition of murine *Bcrp1/Abcg2* and human *BCRP/ABCG2* by the mycotoxin  
510 fumitremorgin C. *Eur. J. Pharmacol.* 644, 41–48. doi:10.1016/j.ejphar.2010.07.016.
- 511 Grahl, N., Shepardson, K. M., Chung, D., and Cramer, R. A. (2012). Hypoxia and Fungal  
512 Pathogenesis: To Air or Not To Air? *Eukaryot. Cell* 11, 560–570. doi:10.1128/EC.00031-  
513 12.
- 514 Gu, X., Fu, Y. X., and Li, W. H. (1995). Maximum likelihood estimation of the heterogeneity of  
515 substitution rate among nucleotide sites. *Mol. Biol. Evol.* 12, 546–57.  
516 doi:10.1093/oxfordjournals.molbev.a040235.
- 517 Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q., and Vinh, L. S. (2018). UFBoot2:  
518 Improving the Ultrafast Bootstrap Approximation. *Mol. Biol. Evol.* 35, 518–522.  
519 doi:10.1093/molbev/msx281.
- 520 Holt, C., and Yandell, M. (2011). MAKER2: an annotation pipeline and genome-database  
521 management tool for second-generation genome projects. *BMC Bioinformatics* 12, 491.

- 522           doi:10.1186/1471-2105-12-491.
- 523   Howard, S. J., and Arendrup, M. C. (2011). Acquired antifungal drug resistance in *Aspergillus*  
524           *fumigatus*: epidemiology and detection. *Med. Mycol.* 49, S90–S95.  
525           doi:10.3109/13693786.2010.508469.
- 526   Ishikawa, M., Ninomiya, T., Akabane, H., Kushida, N., Tsujiuchi, G., Ohyama, M., et al. (2009).  
527           Pseurotin A and its analogues as inhibitors of immunoglobulin E production. *Bioorg. Med.*  
528           *Chem. Lett.* 19, 1457–1460. doi:10.1016/j.bmcl.2009.01.029.
- 529   Johns, A., Scharf, D. H., Gsaller, F., Schmidt, H., Heinekamp, T., Straßburger, M., et al. (2017).  
530           A Nonredundant Phosphopantetheinyl Transferase, PptA, Is a Novel Antifungal Target That  
531           Directs Secondary Metabolite, Siderophore, and Lysine Biosynthesis in *Aspergillus*  
532           *fumigatus* and Is Critical for Pathogenicity. *MBio* 8. doi:10.1128/mBio.01504-16.
- 533   Käfer, E. (1977). Meiotic and Mitotic Recombination in *Aspergillus* and Its Chromosomal  
534           Aberrations. *Adv. Genet.* doi:10.1016/S0065-2660(08)60245-X.
- 535   Kamei, K., and Watanabe, A. (2005). *Aspergillus* mycotoxins and their effect on the host. *Med.*  
536           *Mycol.* 43, 95–99. doi:10.1080/13693780500051547.
- 537   Katoh, K., and Standley, D. M. (2013). MAFFT Multiple Sequence Alignment Software Version  
538           7: Improvements in Performance and Usability. *Mol. Biol. Evol.* 30, 772–780.  
539           doi:10.1093/molbev/mst010.
- 540   Keller, N. P. (2017). Heterogeneity confounds establishment of “a” model microbial strain. *MBio*  
541           8. doi:10.1128/mBio.00135-17.
- 542   Kerr, S. C., Fischer, G. J., Sinha, M., McCabe, O., Palmer, J. M., Choera, T., et al. (2016). FleA  
543           Expression in *Aspergillus fumigatus* Is Recognized by Fucosylated Structures on Mucins  
544           and Macrophages to Prevent Lung Infection. *PLOS Pathog.* 12, e1005555.  
545           doi:10.1371/journal.ppat.1005555.
- 546   Kjærboelling, I., Vesth, T. C., Frisvad, J. C., Nybo, J. L., Theobald, S., Kuo, A., et al. (2018).  
547           Linking secondary metabolites to gene clusters through genome sequencing of six diverse  
548           *Aspergillus* species. *Proc. Natl. Acad. Sci.* 115, E753–E761. doi:10.1073/pnas.1715954115.
- 549   Knox, B. P., Blachowicz, A., Palmer, J. M., Romsdahl, J., Huttenlocher, A., Wang, C. C. C., et  
550           al. (2016). Characterization of *Aspergillus fumigatus* Isolates from Air and Surfaces of the  
551           International Space Station. *mSphere* 1. doi:10.1128/mSphere.00227-16.
- 552   Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., et al. (2012).

- 553 VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome  
554 sequencing. *Genome Res* 22, 568–576. doi:10.1101/gr.129684.111.
- 555 Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., et al.  
556 (2020). COVID-19 associated pulmonary aspergillosis. *Mycoses* 63, 528–534.  
557 doi:10.1111/myc.13096.
- 558 Korf, I. (2004). Gene finding in novel genomes. *BMC Bioinformatics* 5, 59. doi:10.1186/1471-  
559 2105-5-59.
- 560 Kowalski, C. H., Beattie, S. R., Fuller, K. K., McGurk, E. A., Tang, Y.-W., Hohl, T. M., et al.  
561 (2016). Heterogeneity among Isolates Reveals that Fitness in Low Oxygen Correlates with  
562 *Aspergillus fumigatus* Virulence. *MBio* 7. doi:10.1128/mBio.01515-16.
- 563 Kowalski, C. H., Kerkaert, J. D., Liu, K.-W., Bond, M. C., Hartmann, R., Nadell, C. D., et al.  
564 (2019). Fungal biofilm morphology impacts hypoxia fitness and disease progression. *Nat.*  
565 *Microbiol.* 4, 2430–2441. doi:10.1038/s41564-019-0558-7.
- 566 Langford, B. J., So, M., Raybardhan, S., Leung, V., Westwood, D., MacFadden, D. R., et al.  
567 (2020). Bacterial co-infection and secondary infection in patients with COVID-19: a living  
568 rapid review and meta-analysis. *Clin. Microbiol. Infect.* doi:10.1016/j.cmi.2020.07.016.
- 569 Latgé, J.-P., and Chamilos, G. (2019). *Aspergillus fumigatus* and Aspergillosis in 2019. *Clin.*  
570 *Microbiol. Rev.* 33. doi:10.1128/CMR.00140-18.
- 571 Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.  
572 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). The Sequence  
573 Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079.  
574 doi:10.1093/bioinformatics/btp352.
- 575 Lind, A. L., Wisecaver, J. H., Lameiras, C., Wiemann, P., Palmer, J. M., Keller, N. P., et al.  
576 (2017). Drivers of genetic diversity in secondary metabolic gene clusters within a fungal  
577 species. *PLoS Biol.* 15. doi:10.1371/journal.pbio.2003583.
- 578 Liu, D., Zhang, R., Yang, X., Wu, H., Xu, D., Tang, Z., et al. (2011). Thermostable cellulase  
579 production of *Aspergillus fumigatus* Z5 under solid-state fermentation and its application in  
580 degradation of agricultural wastes. *Int. Biodeterior. Biodegradation* 65, 717–725.  
581 doi:10.1016/j.ibiod.2011.04.005.
- 582 Losada, L., Ajayi, O., Frisvad, J. C., Yu, J., and Nierman, W. C. (2009). Effect of competition on  
583 the production and activity of secondary metabolites in *Aspergillus* species. *Med. Mycol.*



- 584 47, S88–S96. doi:10.1080/13693780802409542.
- 585 MacIntyre, C. R., Chughtai, A. A., Barnes, M., Ridda, I., Seale, H., Toms, R., et al. (2018). The  
586 role of pneumonia and secondary bacterial infection in fatal and serious outcomes of  
587 pandemic influenza a(H1N1)pdm09. *BMC Infect. Dis.* 18, 637. doi:10.1186/s12879-018-  
588 3548-0.
- 589 Mead, M. E., Knowles, S. L., Raja, H. A., Beattie, S. R., Kowalski, C. H., Steenwyk, J. L., et al.  
590 (2019). Characterizing the Pathogenic, Genomic, and Chemical Traits of *Aspergillus*  
591 *fischeri*, a Close Relative of the Major Human Fungal Pathogen *Aspergillus fumigatus*.  
592 *mSphere* 4. doi:10.1128/mSphere.00018-19.
- 593 Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler,  
594 A., et al. (2020). IQ-TREE 2: New Models and Efficient Methods for Phylogenetic  
595 Inference in the Genomic Era. *Mol. Biol. Evol.* 37, 1530–1534.  
596 doi:10.1093/molbev/msaa015.
- 597 Mitsuguchi, H., Seshime, Y., Fujii, I., Shibuya, M., Ebizuka, Y., and Kushiro, T. (2009).  
598 Biosynthesis of Steroidal Antibiotic Fusidanes: Functional Analysis of Oxidosqualene  
599 Cyclase and Subsequent Tailoring Enzymes from *Aspergillus fumigatus*. *J. Am. Chem. Soc.*  
600 131, 6402–6411. doi:10.1021/ja8095976.
- 601 Nasir, N., Farooqi, J., Mahmood, S. F., and Jabeen, K. (2020). COVID-19 associated  
602 pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia:  
603 An observational study from Pakistan. *Mycoses* 63, 766–770. doi:10.1111/myc.13135.
- 604 Nierman, W. C., Pain, A., Anderson, M. J., Wortman, J. R., Kim, H. S., Arroyo, J., et al. (2005).  
605 Genomic sequence of the pathogenic and allergenic filamentous fungus *Aspergillus*  
606 *fumigatus*. *Nature* 438, 1151–1156. doi:10.1038/nature04332.
- 607 O’Hanlon, K. A., Cairns, T., Stack, D., Schrettl, M., Bignell, E. M., Kavanagh, K., et al. (2011).  
608 Targeted Disruption of Nonribosomal Peptide Synthetase *pes3* Augments the Virulence of  
609 *Aspergillus fumigatus*. *Infect. Immun.* 79, 3978–3992. doi:10.1128/IAI.00192-11.
- 610 Paul, S., Zhang, A., Ludeña, Y., Villena, G. K., Yu, F., Sherman, D. H., et al. (2017). Insights  
611 from the genome of a high alkaline cellulase producing *Aspergillus fumigatus* strain  
612 obtained from Peruvian Amazon rainforest. *J. Biotechnol.* 251, 53–58.  
613 doi:10.1016/j.jbiotec.2017.04.010.
- 614 Raffa, N., and Keller, N. P. (2019). A call to arms: Mustering secondary metabolites for success

- 615 and survival of an opportunistic pathogen. *PLOS Pathog.* 15, e1007606.  
616 doi:10.1371/journal.ppat.1007606.
- 617 Ries, L. N. A., Steenwyk, J. L., de Castro, P. A., de Lima, P. B. A., Almeida, F., de Assis, L. J.,  
618 et al. (2019). Nutritional Heterogeneity Among *Aspergillus fumigatus* Strains Has  
619 Consequences for Virulence in a Strain- and Host-Dependent Manner. *Front. Microbiol.* 10.  
620 doi:10.3389/fmicb.2019.00854.
- 621 Rokas, A., Mead, M. E., Steenwyk, J. L., Oberlies, N. H., and Goldman, G. H. (2020). Evolving  
622 moldy murderers: *Aspergillus* section *Fumigati* as a model for studying the repeated  
623 evolution of fungal pathogenicity. *PLOS Pathog.* 16, e1008315.  
624 doi:10.1371/journal.ppat.1008315.
- 625 Seidel, D., Durán Graeff, L. A., Vehreschild, M. J. G. T., Wisplinghoff, H., Ziegler, M.,  
626 Vehreschild, J. J., et al. (2017). FungiScope™ -Global Emerging Fungal Infection  
627 Registry. *Mycoses* 60, 508–516. doi:10.1111/myc.12631.
- 628 Sewell, T. R., Zhu, J., Rhodes, J., Hagen, F., Meis, J. F., Fisher, M. C., et al. (2019). Nonrandom  
629 Distribution of Azole Resistance across the Global Population of *Aspergillus fumigatus*.  
630 *MBio* 10. doi:10.1128/mBio.00392-19.
- 631 Shen, X.-X., Oplente, D. A., Kominek, J., Zhou, X., Steenwyk, J. L., Buh, K. V., et al. (2018).  
632 Tempo and Mode of Genome Evolution in the Budding Yeast Subphylum. *Cell* 175, 1533-  
633 1545.e20. doi:10.1016/j.cell.2018.10.023.
- 634 Shwab, E. K., Bok, J. W., Tribus, M., Galehr, J., Graessle, S., and Keller, N. P. (2007). Histone  
635 Deacetylase Activity Regulates Chemical Diversity in *Aspergillus*. *Eukaryot. Cell* 6, 1656–  
636 1664. doi:10.1128/EC.00186-07.
- 637 Sohrabi, C., Alsafi, Z., O’Neill, N., Khan, M., Kerwan, A., Al-Jabir, A., et al. (2020). World  
638 Health Organization declares global emergency: A review of the 2019 novel coronavirus  
639 (COVID-19). *Int. J. Surg.* 76, 71–76. doi:10.1016/j.ijsu.2020.02.034.
- 640 Stanke, M., and Waack, S. (2003). Gene prediction with a hidden Markov model and a new  
641 intron submodel. *Bioinformatics* 19, ii215–ii225. doi:10.1093/bioinformatics/btg1080.
- 642 Steenwyk, J. L., Buida, T. J., LaBella, A. L., Li, Y., Shen, X.-X., and Rokas, A. (2020a).  
643 PhyKIT: a UNIX shell toolkit for processing and analyzing phylogenomic data. *bioRxiv*,  
644 2020.10.27.358143. doi:10.1101/2020.10.27.358143.
- 645 Steenwyk, J. L., Buida, T. J., Li, Y., Shen, X.-X., and Rokas, A. (2020b). ClipKIT: a multiple

- 646 sequence alignment-trimming algorithm for accurate phylogenomic inference. *bioRxiv*,  
647 2020.06.08.140384. doi:10.1101/2020.06.08.140384.
- 648 Steenwyk, J. L., Lind, A. L., Ries, L. N. A., dos Reis, T. F., Silva, L. P., Almeida, F., et al.  
649 (2020c). Pathogenic Allodiploid Hybrids of *Aspergillus* Fungi. *Curr. Biol.* 30, 2495-  
650 2507.e7. doi:10.1016/j.cub.2020.04.071.
- 651 Steenwyk, J. L., Mead, M. E., Knowles, S. L., Raja, H. A., Roberts, C. D., Bader, O., et al.  
652 (2020d). Variation Among Biosynthetic Gene Clusters, Secondary Metabolite Profiles, and  
653 Cards of Virulence Across *Aspergillus* Species. *Genetics*, genetics.303549.2020.  
654 doi:10.1534/genetics.120.303549.
- 655 Steenwyk, J. L., Shen, X.-X., Lind, A. L., Goldman, G. H., and Rokas, A. (2019). A Robust  
656 Phylogenomic Time Tree for Biotechnologically and Medically Important Fungi in the  
657 Genera *Aspergillus* and *Penicillium*. *MBio* 10. doi:10.1128/mBio.00925-19.
- 658 Steenwyk, J., and Rokas, A. (2017). Extensive Copy Number Variation in Fermentation-Related  
659 Genes Among *Saccharomyces cerevisiae* Wine Strains. *G3 Genes, Genomes, Genet.* 7.  
660 Available at: <http://www.g3journal.org/content/7/5/1475#ref-25> [Accessed July 3, 2017].
- 661 Sugui, J. A., Pardo, J., Chang, Y. C., Zarembek, K. A., Nardone, G., Galvez, E. M., et al. (2007).  
662 Gliotoxin Is a Virulence Factor of *Aspergillus fumigatus*: gliP Deletion Attenuates  
663 Virulence in Mice Immunosuppressed with Hydrocortisone. *Eukaryot. Cell* 6, 1562–1569.  
664 doi:10.1128/EC.00141-07.
- 665 Tamura, K., and Nei, M. (1993). Estimation of the number of nucleotide substitutions in the  
666 control region of mitochondrial DNA in humans and chimpanzees. *Mol. Biol. Evol.*  
667 doi:10.1093/oxfordjournals.molbev.a040023.
- 668 Tavaré, S. (1986). Some probabilistic and statistical problems in the analysis of DNA sequences.  
669 *Lect. Math. life Sci.* 17, 57–86.
- 670 Tekaiia, F., and Latgé, J.-P. (2005). *Aspergillus fumigatus*: saprophyte or pathogen? *Curr. Opin.*  
671 *Microbiol.* 8, 385–392. doi:10.1016/j.mib.2005.06.017.
- 672 Urban, M., Cuzick, A., Seager, J., Wood, V., Rutherford, K., Venkatesh, S. Y., et al. (2019).  
673 PHI-base: the pathogen–host interactions database. *Nucleic Acids Res.*  
674 doi:10.1093/nar/gkz904.
- 675 van Dongen, S. (2000). Graph clustering by flow simulation. *Graph Stimul. by flow Clust.* PhD  
676 thesis, University of Utrecht. doi:10.1016/j.cosrev.2007.05.001.

- 677 Vinet, L., and Zhedanov, A. (2011). A ‘missing’ family of classical orthogonal polynomials. *J.*  
678 *Phys. A Math. Theor.* 44, 085201. doi:10.1088/1751-8113/44/8/085201.
- 679 Waddell, P. J., and Steel, M. . (1997). General Time-Reversible Distances with Unequal Rates  
680 across Sites: Mixing  $\Gamma$  and Inverse Gaussian Distributions with Invariant Sites. *Mol.*  
681 *Phylogenet. Evol.* 8, 398–414. doi:10.1006/mpev.1997.0452.
- 682 Waterhouse, R. M., Seppey, M., Simão, F. A., Manni, M., Ioannidis, P., Klioutchnikov, G., et al.  
683 (2018). BUSCO Applications from Quality Assessments to Gene Prediction and  
684 Phylogenomics. *Mol. Biol. Evol.* 35, 543–548. doi:10.1093/molbev/msx319.
- 685 Waterhouse, R. M., Tegenfeldt, F., Li, J., Zdobnov, E. M., and Kriventseva, E. V. (2013).  
686 OrthoDB: a hierarchical catalog of animal, fungal and bacterial orthologs. *Nucleic Acids*  
687 *Res.* 41, D358–D365. doi:10.1093/nar/gks1116.
- 688 Weber, T., Blin, K., Duddela, S., Krug, D., Kim, H. U., Bruccoleri, R., et al. (2015). antiSMASH  
689 3.0—a comprehensive resource for the genome mining of biosynthetic gene clusters.  
690 *Nucleic Acids Res.* 43, W237–W243. doi:10.1093/nar/gkv437.
- 691 Wiemann, P., Lechner, B. E., Baccile, J. A., Velk, T. A., Yin, W.-B., Bok, J. W., et al. (2014).  
692 Perturbations in small molecule synthesis uncovers an iron-responsive secondary metabolite  
693 network in *Aspergillus fumigatus*. *Front. Microbiol.* 5. doi:10.3389/fmicb.2014.00530.
- 694 Yang, Z. (1994). Maximum likelihood phylogenetic estimation from DNA sequences with  
695 variable rates over sites: Approximate methods. *J. Mol. Evol.* 39, 306–314.  
696 doi:10.1007/BF00160154.
- 697 Yin, W.-B., Baccile, J. A., Bok, J. W., Chen, Y., Keller, N. P., and Schroeder, F. C. (2013). A  
698 Nonribosomal Peptide Synthetase-Derived Iron(III) Complex from the Pathogenic Fungus  
699 *Aspergillus fumigatus*. *J. Am. Chem. Soc.* 135, 2064–2067. doi:10.1021/ja311145n.
- 700 Zhou, P., Liu, Z., Chen, Y., Xiao, Y., Huang, X., and Fan, X.-G. (2020). Bacterial and fungal  
701 infections in COVID-19 patients: A matter of concern. *Infect. Control Hosp. Epidemiol.* 41,  
702 1124–1125. doi:10.1017/ice.2020.156.
- 703 Zimin, A. V., Marçais, G., Puiu, D., Roberts, M., Salzberg, S. L., and Yorke, J. A. (2013). The  
704 MaSuRCA genome assembler. *Bioinformatics* 29, 2669–2677.  
705 doi:10.1093/bioinformatics/btt476.
- 706

707 Table 1. Metainformation and NCBI Accessions for CAPA isolates

Isolate	Patient Identifier	Patient Outcome	Patient Age	Patient Sex	Patient immunocompromising condition	Antifungal treatment	Antiviral treatment	NCBI BioSample/Sequence Read Archive Accessions
CAPA A	Patient from this study	Deceased	57	Male	None	Caspofungin (70/50 mg once daily)	Supportive only	SAMN16591136; SRR12949929
CAPA B	Patient #4	Deceased	73	Male	Inhalational steroids for medical history of chronic obstructive pulmonary disease	Voriconazole iv (6/4 mg/kg BW twice daily)	Supportive only	SAMN16591179; SRR12949928
CAPA C	Patient #3	Alive	54	Male	IV corticosteroid therapy 0.4 mg/kg/day, total of 13 days	Caspofungin (70/50 mg once daily) followed by IV voriconazole (6/4 mg/kg BW twice daily)	Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only	SAMN16591190; SRR12949927
CAPA D	Patient #1	Deceased	62	Female	Inhalational steroids for medical history of chronic obstructive pulmonary disease	IV Voriconazole (6/4 mg/kg BW twice daily)	Supportive only	SAMN16591200; SRR12949926

708 Information on CAPA isolates B, C, and D is from (Koehler et al., 2020), where the isolates were first described. CAPA isolate A is  
 709 being reported for the first time. Supportive only antiviral treatment indicates no specific antiviral treatment was given. Abbreviations  
 710 are as follows: BW: body weight; IV: Intravenous; kg: kilogram; mg: milligram.

711

712 Table 2. Biosynthetic gene clusters that produce secondary metabolites implicated in modulating  
713 host biology in *A. fumigatus*

	Function	Reference(s)	Evidence of Biosynthetic Gene Cluster			
			CAPA A	CAPA B	CAPA C	CAPA D
Gliotoxin	Inhibits host immune response	(Sugui et al., 2007)	+	+	+	+
Fumitremorgin	Inhibits the breast cancer resistance protein	(González-Lobato et al., 2010)	+	+	+	+
Trypacidin	Damages lung cell tissues	(Gauthier et al., 2012)	+	+	+	+
Pseurotin	Inhibits immunoglobulin E	(Ishikawa et al., 2009)	+	+	+	+
Fumagillin	Inhibits neutrophil function	(Fallon et al., 2010, 2011)	+	+	+	+

714 '+' and '-' indicates the presence and absence of a BGC, respectively.


715

716 Table 3. Antifungal drug susceptibility of CAPA clinical isolates grown in minimal media

	Af293	CEA17	CAPA A	CAPA B	CAPA C	CAPA D
Amphotericin B	2	2	2-4	2	2	2
Voriconazole	1	0.25-0.50	0.5	0.5	0.25-0.50	0.5
Itraconazole	0.5	0.5	0.5	0.5	0.5	0.5
Posaconazole	1	1	1	1	1	1

717 Minimum inhibitory concentrations are reported as micrograms ( $\mu$ g) per milliliter (mL).






718

719 **Figure 1. Inhalation of *Aspergillus* spores can result in fungal infection.** Inhalation of  
720 *Aspergillus* spores from the environment can travel to the lung and then grow vegetatively and  
721 spread to other parts of the body.

722





733


734 **Figure 3. CAPA isolates have BGCs encoding the toxic small molecule gliotoxin.** Gliotoxin

735 is known to contribute to virulence of *A. fumigatus*. The genomes of CAPA isolates of *A.*

736 *fumigatus* contain biosynthetic gene clusters known to encode gliotoxin. Note, the BGC of

737 CAPA A was split between two contigs and therefore the BGC is hypothesized to be present.

738



739

740 **Figure 4. Strain heterogeneity among CAPA isolates.** CAPA isolates and reference strains  
741 Af293 and CEA17 virulence significantly varied in the *Galleria* moth model of disease ( $p <$   
742  $0.001$ ; log-rank test). Pairwise examinations revealed CAPA D was significantly more virulent  
743 than all other strains (Benjamini-Hochberg adjusted  $p$ -value  $< 0.01$  when comparing CAPA  
744 isolate D to another isolate; log-rank test). Growth of CAPA isolates and reference strains  
745 Af293 and CEA17 in the presence of (B) osmotic, (C) cell wall, and (D) oxidative stressors.  
746 Growth differences between CAPA isolates and reference strains Af293 and CEA17 were  
747 observed across all growth conditions ( $p < 0.001$ ; multi-factor ANOVA). Pairwise differences  
748 were assessed using the post-hoc Tukey Honest Significant Differences test and were only  
749 observed for growth in the presence of CFW at  $25 \mu\text{g/mL}$  ( $p < 0.001$ ; Tukey Honest Significant  
750 Differences test) in which the CAPA isolates did not grow as well as the reference isolates. To  
751 correct for strain heterogeneity in growth rates, radial growth in centimeters in the presence of  
752 stressors was divided by radial growth in centimeters in the absence of the stressor (MM only).  
753 Abbreviations of cell wall stressors are as follows: CFW: calcofluor white; CR: congo red; CSP:  
754 caspofungin. Growth in the presence of other stressors is summarized in Supplementary Figure  
755 4.